Visualitzant O - Articles científics per títol

Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A

Mouron, Silvana; Bueno, MJ; Lluch, Ana; Manso, Luis; Calvo, Isabel; Cortés Castan, Javier (Springer Nature, 2022-12-07)

Physician-perceived utility of the EORTC QLQ-GINET21 questionnaire in the treatment of patients with gastrointestinal neuroendocrine tumours: a multicentre, cross-sectional survey (QUALINETS)

Benavent, Marta; Sastre, Javier; García Escobar, Ignacio; Segura, Angel; Carmona, Alberto; Capdevila Castillon, Jaume (BMC, 2021-01-30)

Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non–small-cell lung cancer

Forde, Patrick; Spicer, Jonathan; provencio, mariano; Mitsudomi, Tetsuya; Awad, Mark; FELIP, ENRIQUETA; Lu, Shun (Future Medicine, 2023-03)

Plain language summary of the design of the TALAPRO-2 study comparing talazoparib and enzalutamide versus enzalutamide and placebo in men with metastatic castration-resistant prostate cancer

Carles Galceran, Joan; Fay, Andre P; Shore, Neal; Agarwal, Neeraj; Azad, Arun; Dunshee, Curtis (Future Science Group, 2022-09)

Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer

Solomon, Benjamin; Bauer, Todd; Mok, Tony; MAZIERES, JULIEN; de Marinis, Filippo; FELIP, ENRIQUETA; Liu, Geoffrey (Future Medicine, 2023-05)

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer

Conteduca, Vincenza; Jayaram, Anuradha; Romero-Laorden, Nuria; Wetterskog, Daniel; Salvi, Samanta; Gurioli, Giorgia; Morales Barrera, Rafael (Elsevier, 2019-03)

Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments

Matito, Judit; Comas Navarro, Raquel; García, Ariadna I.; MARTINI, Giulia; Martin, Anne Marie; Ros, Javier; Villacampa Javierre, Guillermo; Baraibar, Iosune; Saoudi Gonzalez, Nadia; Salvà, Francesc; Toledo, Rodrigo; Tabernero, Josep; Vivancos, Ana; Elez, Elena; Dienstmann, Rodrigo (Elsevier, 2023-06)

Polygenic risk modeling for prediction of epithelial ovarian cancer risk

Dareng, Eileen O.; Tyrer, Jonathan; Jones, Michelle R.; Yang, Xin; Aben, Katja; Balmaña Gelpí, Judith; Diez Gibert, Orland; Barnes, Daniel (Springer Nature, 2022-03)

Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants

Rookus, Matti A.; McGuffog, Lesley; Leslie, Goska; Mooij, Thea M.; Dennis, Joe; Balmaña Gelpí, Judith; Diez Gibert, Orland; Barnes, Daniel (Springer Nature, 2020-10)

Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization

Clavero, Esther; ter Horst, Rob; Sampaio-Marques, Belém; Jurczyszyn, Artur; Sánchez Maldonado, Jose Manuel; Macauda, Angelica; Jerez, Andres (MDPI, 2023-05-09)

Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer

Van Cutsem, Eric; Hochster, Howard S.; Shitara, Kohei; Mayer, Robert; Ohtsu, Atsushi; Falcone, Alfredo; Tabernero Caturla, Josep (Elsevier, 2022-12)

Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid Tumours

leary, alexandra; Trigo, José Manuel; DELORD, Jean-Pierre; Boni, valentina; OAKNIN, ANA; Brana, Irene; Moreno, Victor (Elsevier, 2023-10)

Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure–safety analyses in patients with metastatic pancreatic cancer

Brendel, Karl; Bekaii-Saab, Tanios S; Boland, Patrick M; Dayyani, Farshid; Macarulla Mercadé, Teresa; Dean, Andrew (Wiley, 2021-12)

Portal vein thrombosis in a patient with severe hemophilia B: A challenging balanced management

Suito Alcántara, Milagros; Campoy, Desirée; Benítez Hidalgo, Olga; Martinez Garcia, Maria Fernanda; Olivera, Pável E.; Gironella, Mercedes; Juarez-Gimenez, Juan Carlos (Wiley, 2024-02)

Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy

Garcia‑Carbonero, Rocio; Simo Perdigo, Marc; Del Olmo García, Maria Isabel; Jimenez-Fonseca, Paula; Pubul Núñez, Virginia; Capdevila Castillon, Jaume; Grande, Enrique; Carmona-Bayonas, Alberto (Oxford University Press, 2022-04)

Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer

Gonzalez, David; Mateo Valderrama, Joaquim; Stenzinger, Albrecht; Rojo, Federico; Shiller, Michelle; Wyatt, Alexander W (Wiley, 2021-07)

Pralsetinib in patients with RET fusion–positive non-small-cell lung cancer: A plain language summary of the ARROW study

Griesinger, Frank; Baik, Christina; Tan, Daniel; Lee, Dae Ho; Curigliano, Giuseppe; Subbiah, Vivek; GARRALDA, Elena (Future Medicine, 2024-02)

(Pre)treatment risk factors for late fatigue and fatigue trajectories following radiotherapy for breast cancer

Rosas , Juan Camilo; Aguado-Barrera, Miguel E; Briers, Erik; Elliott, Rebecca; Farcy-Jacquet, Marie-Pierre; Giraldo Marin, Alexandra; Azria, David; Gutiérrez-Enríquez, Sara; Reyes López, Victoria (Wiley, 2023-11-01)

Precise enhancement quantification in post-operative MRI as an indicator of residual tumor impact is associated with survival in patients with glioblastoma

Garcia Ruiz, Alonso; Naval‑Baudin, Pablo; Pons‑Escoda, Albert; Bruna, Jordi; Plans, Gerard; Pérez López, Raquel; Ligero, Marta (Nature Research, 2021-01-12)

Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors

Muik, Alexander; Garralda Cabanas, Elena; Altintas, Isil; Gieseke, Friederike; Geva, Ravit; Ben-Ami, Eytan; Alonso-Casal, Guzman (American Association for Cancer Research, 2022-05-01)

Scientia. Dipòsit d'Informació Digital del Departament de Salut

Visualitzant VHIO - Articles científics per títol

Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A

Physician-perceived utility of the EORTC QLQ-GINET21 questionnaire in the treatment of patients with gastrointestinal neuroendocrine tumours: a multicentre, cross-sectional survey (QUALINETS)

Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non–small-cell lung cancer

Plain language summary of the design of the TALAPRO-2 study comparing talazoparib and enzalutamide versus enzalutamide and placebo in men with metastatic castration-resistant prostate cancer

Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer

Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments

Polygenic risk modeling for prediction of epithelial ovarian cancer risk

Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants

Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization

Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer

Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid Tumours

Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure–safety analyses in patients with metastatic pancreatic cancer

Portal vein thrombosis in a patient with severe hemophilia B: A challenging balanced management

Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy

Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer

Pralsetinib in patients with RET fusion–positive non-small-cell lung cancer: A plain language summary of the ARROW study

(Pre)treatment risk factors for late fatigue and fatigue trajectories following radiotherapy for breast cancer

Precise enhancement quantification in post-operative MRI as an indicator of residual tumor impact is associated with survival in patients with glioblastoma

Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors

Coneix Scientia

Guies i ajudes

Directe a...

Coneix Scientia

Guies i ajudes

Directe a...

Visualitzant VHIO - Articles científics per títol

Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A ﻿

Physician-perceived utility of the EORTC QLQ-GINET21 questionnaire in the treatment of patients with gastrointestinal neuroendocrine tumours: a multicentre, cross-sectional survey (QUALINETS) ﻿

Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non–small-cell lung cancer ﻿

Plain language summary of the design of the TALAPRO-2 study comparing talazoparib and enzalutamide versus enzalutamide and placebo in men with metastatic castration-resistant prostate cancer ﻿

Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer ﻿

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer ﻿

Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments ﻿

Polygenic risk modeling for prediction of epithelial ovarian cancer risk ﻿

Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants ﻿

Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization ﻿

Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer ﻿

Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid Tumours ﻿

Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure–safety analyses in patients with metastatic pancreatic cancer ﻿

Portal vein thrombosis in a patient with severe hemophilia B: A challenging balanced management ﻿

Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy ﻿

Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer ﻿

Pralsetinib in patients with RET fusion–positive non-small-cell lung cancer: A plain language summary of the ARROW study ﻿

(Pre)treatment risk factors for late fatigue and fatigue trajectories following radiotherapy for breast cancer ﻿

Precise enhancement quantification in post-operative MRI as an indicator of residual tumor impact is associated with survival in patients with glioblastoma ﻿

Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors ﻿

Coneix Scientia

Guies i ajudes

Directe a...

Coneix Scientia

Guies i ajudes

Directe a...

Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A

Physician-perceived utility of the EORTC QLQ-GINET21 questionnaire in the treatment of patients with gastrointestinal neuroendocrine tumours: a multicentre, cross-sectional survey (QUALINETS)

Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non–small-cell lung cancer

Plain language summary of the design of the TALAPRO-2 study comparing talazoparib and enzalutamide versus enzalutamide and placebo in men with metastatic castration-resistant prostate cancer

Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer

Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments

Polygenic risk modeling for prediction of epithelial ovarian cancer risk

Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants

Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization

Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer

Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid Tumours

Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure–safety analyses in patients with metastatic pancreatic cancer

Portal vein thrombosis in a patient with severe hemophilia B: A challenging balanced management

Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy

Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer

Pralsetinib in patients with RET fusion–positive non-small-cell lung cancer: A plain language summary of the ARROW study

(Pre)treatment risk factors for late fatigue and fatigue trajectories following radiotherapy for breast cancer

Precise enhancement quantification in post-operative MRI as an indicator of residual tumor impact is associated with survival in patients with glioblastoma

Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors